Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrroldine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

CLAUDINE SERRADEIL-LE GAL, JEAN WAGNON, JACQUES SIMIAND, GUY GRIEBEL, COLETTE LACOUR, GILLES GUILLO, CLAUDE BARBERIS, GABRIELLE BROSSARD, PHILIPPE SOUBRIÉ, DINO NISATO, MARC PASCAL, REBECCA PRUSS, BERNARD SCATTON, JEAN-PIERRE MAFFRAND, and GERARD LE FUR

ABSTRACT

(2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrroldine carboxamide (SSR149415), the first selective, nonpeptide vasopressin V1b receptor antagonist yet described, has been characterized in vitro and in vivo. SSR149415 showed competitive nanomolar affinity for animal and human V1b receptors and exhibited much lower affinity for rat and human V1a, V2, and oxytocin receptors. Moreover, this compound did not interact with a large number of other receptor types or ion channels. In vitro, SSR149415 behaved as a full antagonist and potently inhibited arginine vasopressin (AVP)-induced Ca2+ increase in Chinese hamster ovary cells expressing rat or human V1b receptors. The in vivo activity of SSR149415 has been studied in several models of elevated corticotropic secretion in conscious rats. SSR149415 inhibited exogenous AVP-induced increase in plasma corticotropin, from 3 mg/kg i.p. and 10 mg/kg p.o. upwards. Similarly, this compound antagonized AVP-potentiated corticotropin release provoked by exogenous corticoliberin at 3 mg/kg p.o. The effect lasted for more than 4 h at 10 mg/kg p.o. showing a long-lasting oral effect. SSR149415 (10 mg/kg p.o.) also boosted corticotropin secretion induced by endogenous AVP increase subsequent to body water loss. Moreover, 10 mg/kg i.p SSR149415 inhibited plasma corticotropin elevation after restraint-stress in rats by 50%. In the four-plate test, a mouse model of anxiety, SSR149415 (3 mg/kg p.o. upwards) displayed anxiolytic-like activity after acute and 7-day repeated administrations. Thus, SSR149415 is a potent, selective, and orally active V1b receptor antagonist. It represents a unique tool for exploring the functional role of V1b receptors and deserves to be clinically investigated in the field of stress and anxiety.

ABBREVIATIONS: AVP, arginine vasopressin; OT, oxytocin; CNS, central nervous system; DMSO, dimethyl sulfoxide; RIA, radioimmunoassay; dDAVP, desamino-[0-Arg8]-vasopressin; dPal, [deamino-Cys, 0-3-(pyridyl)-Ala2-Arg9]-vasopressin; dPen, [deamino-phenylalanine-O-Me-Tyr², Arg⁹]-vasopressin; fura-2/AM, fura 2-acetoxymethyl ester; BSA, bovine serum albumin; CHO, Chinese hamster ovary; ANOVA, analysis of variance; intracellular Ca2+, [Ca2+]; HPA, hypothalamo-pituitary-adrenal; SR 121463, (1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzene sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinooethoxy)cyclohexane]indol-2-one, equatorial isomer.
kidney where it mediates the antidiuretic effect of AVP. The ubiquitous V_{1a} receptors mediate the actions of AVP in platelets, vessels, liver, adrenals, uterus, and brain, and like V_{1b} receptors, induce phospholipase C activation and intracellular calcium mobilization (Lolait et al., 1995a; Thibonnier et al., 1998). The recently cloned V_{1b} receptor is mainly involved in the stimulating effect of AVP on corticotropin secretion in the pituitary (De Keyzer et al., 1994; Sugimoto et al., 1994). AVP is a direct corticotropin secretagogue and also synergizes corticotropin-induced corticotropin release in many species, including human (Gillies et al., 1982; Rivier and Vale, 1983; Antoni et al., 1984; Gaillard et al., 1984; Dickstein et al., 1996). Regulation of corticotropin secretion is a critical component in the adaptive organism response to stress or emotional situations. Data have shown that AVP plays a primary role during adaptation to stress (Aguilera and Rabadan-Diehl, 2000). In chronic stress, the expression of AVP in parvocellular neurons of the paraventricular nucleus and its secretion into pituitary portal circulation increases. In addition, stress regulates pituitary V_{1b} receptors, increasing the corticotropin-releasing activity of AVP (De Goeij et al., 1992; Rabadan-Diehl et al., 1995). As demonstrated by in situ hybridization and immunohistochemistry, V_{1b} receptor mRNA and protein are widely distributed in the rat CNS, suggesting that not only V_{1a} but also V_{1b} receptors mediate different AVP functions in the rat brain (Lolait et al., 1995b; Vaccari et al., 1998; Hernando et al., 2001). Of note, the presence of V_{1b} receptors has been also reported in several small cell lung cancer tumors (North et al., 1998) and the V_{1b} (V_{2}) receptor gene is overexpressed in corticotropin-secreting tumors (De Keyzer et al., 1998). An endocrine role of V_{1b} receptors in other organs such as the pancreas and the adrenals in regulating glucagon and insulin release has also been suggested (Lee et al., 1995; Yihchok-anun et al., 1999). To date, due to the lack of selective V_{1b} receptor ligands (agonists/antagonists) and to the absence of orally active V_{1b} receptor antagonists, the V_{1b} receptor is still poorly characterized and the precise role of AVP via central and peripheral V_{1b} receptors remains to be elucidated. Interestingly, to explore the functions of this receptor, a knockout mouse has been generated. Preliminary data showed that these animals display behavioral alterations, e.g., reduced aggression and social memory that could be attributed to the absence of V_{1b} receptors in specific brain structures (Lolait et al., 2000; Hernando et al., 2001).

In the present study we report the biochemical and pharmacological characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrroli dine carboxamide, isomer (−) (SSR149515) (Fig. 1), the first selective, nonpeptide, and orally active V_{1b} receptor antagonist yet described. Because marked species differences exist for AVP/OT receptors in terms of binding affinity and pharmacological properties, SSR149415 was also studied in various animal and human preparations expressing V_{1b} receptors. Inasmuch as V_{1b} receptors control corticotropin release, the in vivo activity of SSR149415 has been studied in rats in several models of corticotropin secretion induced by various factors (AVP, AVP plus corticotropin, body water loss- and restraint-stress). Finally, the anxiolytic-like properties of SSR149415 were investigated in the four-plate test in mice, a well validated model of anxiety. We clearly demonstrate that SSR149415 is a unique tool for exploring the role and the localization of V_{1b} receptors and that this type of drug exhibits a promising therapeutic profile in the field of anxiety and stress-related disorders.

**Experimental Procedures**

The nonpeptide molecules, SSR149415 and SR121463 (Serradeil-Le Gall et al., 1996) were synthesized at Sanofi-Synthelabo Recherche, Montpellier and Toulouse, respectively, France. The chemical structures were determined by 1H and 13C NMR, mass spectrometry, and infrared spectroscopy. The purity, measured by high-pressure liquid chromatography, thin layer chromatography, and elemental analysis, was >98%. For in vitro experiments the compound was initially dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10^{-2} M and then diluted in the appropriate test solvent. AVP, oxytocin, desamino-[D-Arg^9]-vasopressin (dDAVP), [deamino-Cys, d-3-(pyrrolid-1-yl)-Ala^2]-vasopressin (dPal), [deamino-penicillamine,O-Me-Tyr]^2, Arg^3]-vasopressin (dPen), bacitracin, Pluronic F-127, and Creminophor EL were from Sigma Chemical (St. Louis, MO). Corticotropin was purchased from NeoSystem (Strasbourg, France). Fura-2/acetoxymethyl ester (fura-2/AM) was from Molecular Probes (Eugene, OR). Bovine serum albumin (BSA) fraction V was obtained from IBF (Paris, France). All cell culture reagents were from Roche Molecular Biochemicals (Meylan, France). Tris, MgSO_4, and DMSO were purchased from Merck-Clevenot (Nogent-sur-Marne, France). All other chemicals were from Prolabo (Nogent-sur-Marne, France). The radioligands [3H]AVP [8-i-arginine, [phenylalananyl-3,4,5-3H(N)]-vasopressin; 75 Ci/mmol], [3H]SR121463 (47.5 Ci/mmol), and 125I-OT antagonist, [dCH_{2}Tyr(Me)_{2}, Thr^{4}, Orn^{8},[125I]-Tyr^{9}, NH_{2}] (2000 Ci/mmol), were synthesized by PerkinElmer Life Sciences (Boston, MA).

**Materials**

Male Sprague-Dawley CD rats (150–200 g, except in restraint-stress experiments in which animals weighed between 275 to 300 g) were purchased from Charles River (St. Aubin Les Elbeufs, France). They were used for in vivo activity and membrane preparations in in vitro binding studies. Male NMRI mice (20 ± 3 g) purchased from R. Janvier (Le Genest, France) were used in the four-plate test. Male homozygous Brattleboro rats with central diabetes insipidus (300–350 g) were purchased from R. Janvier (Le Genest, France) and were housed in climate- and stress experiments in which animals weighed between 275 to 300 g). They were used in the four-plate test. Male homozygous Brattleboro rats with central diabetes insipidus (300–350 g) were purchased from R. Janvier (Le Genest, France). The radioligands [8-i-arginine, [phenylalananyl-3,4,5-3H(N)]-vasopressin; 75 Ci/mmol], and 125I-OT antagonist, [dCH_{2}Tyr(Me)_{2}, Thr^{4}, Orn^{8},[125I]-Tyr^{9}, NH_{2}] (2000 Ci/mmol), were synthesized by PerkinElmer Life Sciences (Boston, MA).

**Biological Material**

Male Sprague-Dawley CD rats (150–200 g, except in restraint-stress experiments in which animals weighed between 275 to 300 g) were purchased from Charles River (St. Aubin Les Elbeufs, France). They were used for in vivo activity and membrane preparations in in vitro binding studies. Male NMRI mice (20 ± 3 g) purchased from R. Janvier (Le Genest, France) were used in the four-plate test. Male homozygous Brattleboro rats with central diabetes insipidus (300–350 g) were purchased from R. Janvier (Le Genest, France). They were used in the four-plate test. Male homozygous Brattleboro rats with central diabetes insipidus (300–350 g) were purchased from R. Janvier (Le Genest, France). The radioligands [8-i-arginine, [phenylalananyl-3,4,5-3H(N)]-vasopressin; 75 Ci/mmol], and 125I-OT antagonist, [dCH_{2}Tyr(Me)_{2}, Thr^{4}, Orn^{8},[125I]-Tyr^{9}, NH_{2}] (2000 Ci/mmol), were synthesized by PerkinElmer Life Sciences (Boston, MA).

Human hypophyses were collected in conformity with French national ethical rules. Hypophyses were obtained within 6 h of death, chilled in cold saline, and immediately frozen in liquid nitrogen. Bovine hypophyses were obtained from a local slaughterhouse. Mari-
mary tissue was taken from 19-day-old Sprague-Dawley pregnant rats and stored in liquid nitrogen until use.

**In Vitro Experiments**

**Cell Culture and Membrane Preparation.** Ltk<sup>−</sup> cells were transfected with the cDNA coding for the human OT receptor. CHO-dhFr<sup>−</sup> cells (DXB11) were transfected with an expression vector derived from plasmid 7055 containing the cDNA encoding the human V<sub>2</sub>, V<sub>1a</sub>, or V<sub>1b</sub> receptor. Stably transformed cell lines were isolated as described previously (Serradeil-Le Gal et al., 1996, 2000). They were grown in 10 mM HEPES, pH 7.4, minimal essential medium supplemented with 5% fetal calf serum and 8 g/l sodium bicarbonate and 300 µM Na<sub>2</sub>HPO<sub>4</sub>, 5.5 mM glucose, 4.2 mM NaHCO<sub>3</sub>, 0.8 M MgSO<sub>4</sub>, 10 mM HEPES (0.1 mM EGTA for the first wash only), pH 7.4. The cells were resuspended in this buffer to a final concentration of 2.7 × 10<sup>6</sup> cells/ml and kept at 4 °C in the dark until use. Calcium transients were measured with an SLM 8000 C spectrofluorometer at 37 °C (excitation at 340 and 380 nm, emission at 510 nm). Cytosolic free Ca<sup>2+</sup> determination was performed as described by Grynkiewicz et al. (1985). Results were expressed as means ± S.E. and analyzed using RSI software (BBN Domain, Cambridge, MA).

**In Vivo Experiments**

**In Vivo Interaction of SSR149415 with AVP V<sub>1a</sub> and V<sub>2</sub> Receptors.** Potential in vivo interaction of SSR149415 with AVP vascular V<sub>1a</sub> and renal V<sub>2</sub> receptors was studied in male Sprague-Dawley rats. The effects of SSR149415 (30 mg/kg p.o. in 0.6% methylcellulose) were studied on AVP (40 ng/kg i.v.)-induced hypertension and on spontaneous urine flow rate during a 6-h observation period as previously described (Serradeil-Le Gal et al., 1993, 1996). To detect potential antidiuretic agonist V<sub>2</sub> properties, additional experiments have been performed in vasopressin-deficient Brattleboro rats with SSR149415 (10 mg/kg i.p. in 5% DMSO, 5% Creomorph in saline); urine was collected for the next 24 h for volume and osmolality measurements (Serradeil-Le Gal et al., 1996).

**In Vivo Plasma Corticotropin Measurements in Conscious Rats.** Exogenous AVP-induced corticotropin secretion and plasma corticotropin measurements. In a first set of experiments, dose effects were performed with SSR149415 (1–30 mg/kg) administered either 30 min i.p. or 2 h p.o. before an exogenous AVP injection (0.3 µg/kg i.v. in 0.1% bovine serum albumin in distilled water). Ten minutes after the AVP challenge, the vehicle- (5% DMSO, 5% Creomorph in saline) and SSR149415-treated rats were sacrificed by decapitation and trunk blood collected in a 10-ml EDTA solution (1, 1/10; volume/volume dilution). After centrifugation (760 g × 10 min; 2–4°C) plasma was collected and stored as aliquots at −20°C until Corticotropin measurements by RIA (DiaSorin S.A., Stillwater, MN) were made. Under similar operating conditions, time course studies were performed with i.p. and oral 10 mg/kg SSR149415 administered 1, 2, 3, 4, and 6 h before the AVP challenge.

**Potentiation of exogenous corticoliberin by AVP on corticotropin secretion.** In preliminary experiments, we studied the dose-effect and the kinetics of corticoliberin-induced corticotropin secretion, alone and in combination with AVP. Exogenous corticoliberin (dissolved in 0.1% acetic acid and 0.1% BSA in distilled water) produced a significant increase in corticotropin plasma levels from the dose of 0.3 µg/kg i.v. and the effect was maximal 30 min after corticoliberin injection. As previously described for AVP, the maximal effect on corticotropin secretion was observed 10 min after administration (Bernardini et al., 1994). By combining doses of corticoliberin (0.1 µg/kg i.v. administered 30 min before sacrifice) and AVP (0.03 µg/kg i.v. administered 10 min before sacrifice), devoid of significant effect on corticotropin secretion when injected alone, we observed a significant synergization of corticoliberin effects by AVP, as reported previously (Rivier and Vale, 1983). In the dose-effect experiments, the animals (11–19/group) were treated either with the vehicle (5% DMSO, 5% Creomorph in saline) or with SSR149415 (1–10 mg/kg) 2 h before the AVP (plus corticoliberin) challenge. Similarly the time course study was performed with oral 10 mg/kg p.o. SSR149415 administered 1, 2, 3, 4, and 6 h before the AVP (plus corticoliberin) challenge. Ten minutes after AVP administration animals were sacrificed and plasma corticotropin measured as described above.

**SR121463-Induced Corticotropin Secretion.** SR121463 is a selective and orally active V<sub>2</sub> receptor antagonist displaying power-
ful aquaretic properties in several species. In rats, it has been previously observed that high doses of SR121463 (≥3 mg/kg p.o.) induced important water loss, leading to endogenous AVP release associated with increased plasma corticotropin, which is maximal 2 h after oral SR121463 administration (Lacour et al., 2000). In this set of experiments, groups of 16 to 19 animals pretreated or not with SSR149415 (1–30 mg/kg p.o.) received 1 h later a high dose of SR121463 (10 mg/kg p.o.). Animals were sacrificed 2 h after SR121463 administration and plasma corticotropin measured as described above. Control animals were administered with SR121463 and SSR149415 vehicles at the corresponding times.

**Restraint Stress-Induced Corticotropin Secretion in Rats.** All experiments were conducted between 8:30 AM and 11:00 AM. Rats (8–10/group) received intraperitoneal injection of the vehicle (2 ml/kg; 5% DMSO, 5% Cremophor, 90% saline) or 10 mg/kg SSR149415. Thirty minutes after the injection, rats were placed in transparent Plexiglas restrainers (6 cm in width by 4 cm in height) for 15 min. At the end of the immobilization period, they were placed individually in a cage, carried to an adjacent room, and immediately sacrificed by decapitation. Nonstressed (home-cage) control rats were sacrificed 45 min after their i.p. injection. Blood was collected and corticotropin plasma levels measured as described above.

**Four-Plate Test in Mice.** The test apparatus is based on the one described by Boisier et al. (1968). The apparatus consists of a cage with a floor composed of four rectangular metal plates connected to a device that can generate electric shocks (1 mA; 0.2 s). After a 15-s latency period, the animal is subjected to an electric shock every time it moves from one plate to another. The number of punished crossings is recorded during a 1-min test period. Experiments were carried out, respectively, 30 or 60 min after i.p. or p.o. injection of SSR149415. In a second experiment, the duration of the anxiolytic-like action of 10 mg/kg p.o. SSR149415 was investigated. Mice were administered with the compound and placed in the apparatus 1, 2, 4, or 6 h later. Each animal was tested once. In a third experiment, possible development of tolerance to the anxiolytic-like activity was investigated after repeated administration of SSR149415. The drug was given orally at the dose of 10 mg/kg, once daily for 7 consecutive days. Animals were tested 1 h after the 7th administration.

**In Vivo Data Statistical Analysis.** Data, expressed as the mean ± S.E.M., were analyzed by a single-factor ANOVA or with the nonparametric Kruskal-Wallis test. Subsequent comparisons between treatment groups and control were carried out using Dunnett’s or Student’s t test procedure, or the nonparametric Mann-Whitney U test with a adjustment of Holm, respectively, using RS1 software.

**Results**

**Interaction of SSR149415 with Animal and Human AVP V1b Receptors and Selectivity Profile.** As shown in Table 1 and Fig. 2A, SSR149415 displays high nanomolar affinity for animal and human V1b receptors. This compound dose dependently antagonized [3H]AVP binding to various membrane preparations from CHO cell lines transfected with the rat and human V1b receptors or from human, rat, and bovine pituitary tissues expressing native V1b receptors. As illustrated in Fig. 2A, SSR149415 had an affinity for human V1b receptors close to that of the natural hormone, AVP (Kᵢ values of 1.54 ± 0.82 and 0.80 ± 0.25 nM, respectively). In contrast, SSR149415 exhibited higher affinity than the nonselective reference agonist (dDAVP, dPald) and antagonist (dPen) V1b peptides (Kᵢ values of 20 ± 8, 12 ± 5 and 21 ± 6 nM, respectively). Kᵢ values obtained for these peptides are consistent with affinities previously reported for the human V1b receptor (Thibonnier et al., 1997, 1998). Hill coefficients from binding competition experiments were close to unity, indicating a single-site competitive model. Moreover, saturation binding experiments were performed in CHO cells transfected with the human V1b receptor in the absence or presence of SSR149415 (0.9, 1.8, 3.7, 7.5, and 15 nM). Scatchard analysis of these data indicated that SSR149415 inhibited [3H]AVP binding in a competitive manner; however, the Kᵢ value calculated from Scatchard plots (2.51 ± 0.45 nM) was consistent with the Kᵢ value obtained according to the Cheng and Prussoff (1973) equation in competition experiments (1.54 ± 0.82 nM) (Table 1).

The selectivity of SSR149415 was first assessed for other AVP (V₁a and V₂) and OT receptors from rat and human origin. As shown in Table 1, SSR149415 exhibited only a weak affinity for these receptors and displayed a 70, 1000, and 100 higher affinity for human V₁b versus V₁a, V₂, and OT human receptors, respectively. SSR149415 discriminated between rat and human V₁a receptors consistent with previous species differences reported in the field of AVP/OT (Table 1). To complete the functional characterization of SSR149415 at OT and V₁a receptors, we have previously studied this compound on Ca²⁺ transients in cells stably transfected with human OT or V₁a receptors. In both cell lines, 1 μM SSR149415 was unable to increase intracellular Ca²⁺ when tested alone and decreased AVP- or OT-induced Ca²⁺ increase, showing a total absence of agonist effect and an antagonist profile at high concentrations.

The high degree of specificity of SSR149415 for the V₁b receptor was also demonstrated in several additional assays (n = 100). In a variety of binding tests, SSR149415 (10 μM) did not interact with receptors of nonpeptide (adenosine, adrenergic, angiotensin, benzodiazepin, cannabinoid, dopamine, histamine, acetylcholine, serotonin, glucocorticoid, Ca²⁺, Na⁺ Cl⁻, and K⁺ channels) or peptide ligands (neurotensin, endothelin, neurotensin, bradykinin, galanin, nociceptin, and somatostatin) nor with several enzymes (cytochrome oxidase, phosphodiesterases, angiotensin-converting enzyme, protein kinase C, monoamine oxidase, ATPase, and...
acetylcholinesterase). The selectivity profile of SSR149415 was further investigated in vivo by studying the effect of this compound on the pressor response to exogenous AVP and on diuresis in rats, to assess a potential interaction with V1a and V2 receptors, respectively. SSR149415 (up to 30 mg/kg p.o.) neither modified the hypertensive response to exogenous AVP (40 ng/kg i.v.) nor urine excretion volume in conscious rats. Moreover, in vasopressin-deficient Brattleboro rats, a sensitive model used for detecting potential agonist antidiuretic activity, 10 mg/kg i.p. SSR149415 had no effect on urine flow rate (data not shown).

**Effect of SSR149415 on AVP-Induced [Ca2+]i Increase in CHO Cells Expressing V1b Receptors**

To determine the agonist or antagonist profile of SSR149415, we studied the activity of this compound on the rat and the human V1b receptors. In these preparations, AVP dose dependently increased [Ca2+]i, with an EC50 value of 0.41 ± 0.21 nM, and 0.44 ± 0.17 nM respectively. As shown in Fig. 3, SSR149415 antagonized in a dose-dependent manner 30 nM AVP-evoked [Ca2+]i elevation in CHO cells expressing the human V1b receptor, giving a Ki value of 1.26 ± 0.60 nM (n = 5). Similar results were obtained in CHO cells transfected with the rat V1b receptors (Ki = 2.0 ± 0.6 nM). When tested alone up to 10−5 M, SSR149415 was unable to increase [Ca2+]i in these cells, showing a total absence of agonistic effect.

Fig. 2. Effect of SSR149415 on [3H]AVP binding to human AVP V1b receptors expressed in CHO cells. A, inhibition of [3H]AVP-specific binding to human V1b receptors by SSR149415 (○) and reference peptide compounds: ○, AVP; □, dDAVP; ○, dPen; ○, dPal. B, Scatchard plots of [3H]AVP binding to CHO V1b membranes without (○) or with 0.9 nM (▼), 1.8 nM (□), 3.7 nM (▲), 7.5 nM (■), and 15 nM (▲) SSR149415. Binding assays were performed for 45 min at 20°C in the presence of 30 μg/assay of CHO membranes as described under Experimental Procedures. Results represent data from a typical experiment performed in duplicate, which was repeated three times without noticeable change.

Fig. 3. Inhibition by SSR149415 of AVP-induced Ca2+ i increase in CHO cells transfected with the human V1b receptor. Dispersed CHO cells (4–5 × 105 cells/ml), preloaded with 2 μM fura-2/AM, were incubated 20 min at 30°C with or without increasing concentrations of SSR149415 before stimulation with 30 nM AVP as described under Experimental Procedures. Inset, dose-response curve of AVP. Results represent data from a typical experiment that was repeated five to eight times without noticeable change.

**In Vivo Experiments on Corticotropin Secretion in Conscious Rats**

**Effect of SSR149415 on Exogenous AVP-Induced Corticotropin Secretion in Rats.** A direct stimulating effect of AVP on corticotropin secretion in corticotelocell has been extensively described both in vitro and in vivo (Gillies et al., 1982; Rivier and Vale, 1983; Antoni et al., 1984; Gaillard et al., 1984; Dickstein et al., 1996). We demonstrated that in conscious rats exogenous AVP dose dependently increased corticotropin secretion; the effect was maximal 10 min after AVP injection, in agreement with previous reports (Bernardini et al., 1994). At 0.3 μg/kg i.v., AVP increased basal corticotropin levels by about 3-fold from 76 ± 11 to 231 ± 26 pg/ml. As shown in Fig. 4, 1 to 30 mg/kg SSR149415 antagonized AVP-induced corticotropin secretion in a dose-dependent manner by both intraperitoneal and oral routes. The inhibition was significant from 10 μg/kg p.o. and 3 μg/kg i.p. upwards. It is important to note that the inhibitory action of SSR149415 lasted significantly for more than 2 h at 10 μg/kg i.p. and up to 4 h at 10 mg/kg p.o. (data not shown). When tested alone, SSR149415 had no effect on basal corticotropin plasma levels up to 30 mg/kg p.o. (76 ± 11 and 76 ± 15 pg/ml corticotropin for vehicle (n = 20) and SSR149415-treated (n = 6) rats, respectively).

**Effect of SSR149415 on AVP-Induced Potentiation of Corticoleberin Effect on Corticotropin Secretion in Rats.** The ability of AVP to enhance the action of corticoleberin on corticotropin secretion in vitro and in vivo is well established and this property is considered as a typical V1b-mediated effect. We developed such a model in conscious rats and observed that 0.03 μg/kg i.v. AVP synergized with 0.1 μg/kg i.v. corticoleberin to promote corticotropin release, whereas each dose alone had no significant effect on cortico-
tropin secretion. Oral administration of SSR149415 (1–30 mg/kg) produced powerful dose-dependent inhibition of the corticotropin increase in response to exogenous AVP plus corticoliberin; the effect was significant from the dose of 3 mg/kg p.o. (Fig. 5A). Complete blockade was achieved at 10 mg/kg. The oral time course of 10 mg/kg SSR149415 showed a fast onset of action, the inhibitory effect of SSR149415 being already maximal at 1 h after administration. The inhibitory effect on corticotropin secretion lasted significantly more than 4 h, demonstrating a long-lasting oral effect in a specific V1b-related model (Fig. 5B).

Effect of SSR149415 on Endogenous AVP-Induced Corticotropin Secretion in Rats. In rats, high doses (≥3 mg/kg) of SR121463, a selective V2 receptor antagonist with powerful aquaretic properties, induce a strong and rapid water loss resulting in endogenous AVP secretion to avoid body dehydration and significantly increased plasma corticotropin levels (Lacour et al., 2000). As shown in Fig. 6, 10 mg/kg p.o. SR121463 induced a strong elevation (about 6-fold) in plasma corticotropin in conscious rats (46 ± 6–288 ± 24 pg/ml corticotropin, n = 16). In animals pretreated with 1 to 30 mg/kg SSR149415 a dose-dependent inhibition in plasma corticotropin secretion was observed, significant from the dose of 10 mg/kg p.o.

Effect of SSR149415 on Restraint Stress-Induced Corticotropin Secretion in Rats. As previously observed, various physical stresses are able to induce corticotropin secretion. The stress-induced release of corticotropin is believed to involve the activation of several humoral and neural pathways, including that mediated by AVP (Rivier and Vale, 1983; Linton et al., 1985). As shown in Table 2, in rats submitted to an immobilization period of 15 min there was a significant increase (more than 5-fold) in plasma corticotropin levels (P <0.01 versus control). Pretreatment with SSR149415 at 10 mg/kg i.p., 30 min before the stress period caused a 50% inhibition of plasma corticotropin elevation in comparison with stressed animals treated with the corresponding vehicle.

Effect of SSR149415 in Four-Plate Test in Mice. The anxiolytic properties of SSR149415 were studied in the four-plate test, a model of anxiety based on unconditioned fear. It
is sensitive to the action of classical (i.e., benzodiazepines) and atypical (i.e., 5-hydroxytryptamine reuptake inhibitors and metabotropic glutamate receptor ligands) anxiolytics (Bourin et al., 1992; Tatarczynska et al., 2001). In the acute experiments, i.p. and p.o. SSR149415 increased the number of punished crossings showing marked anxiolytic effects (Fig. 7). Post hoc analysis revealed that these effects reached statistical significance with SSR149415 from 3 mg/kg p.o. and i.p. Moreover, when SSR149415 was given repeatedly at 10 mg/kg p.o. for 7 days, the anxiolytic-like activity was still significantly maintained (P < 0.01). Finally, the oral time course of the anxiolytic-like action of SSR149415 performed at 10 mg/kg indicated that effects lasted for more than 4 h (Fig. 7).

Discussion

AVP is an important physiological regulator of the hypothalamo-pituitary-adrenal (HPA) axis, whose stimulation is a major component of the mammalian adaptive responses to stress (Aguilera and Rabadan-Diehl, 2000). AVP stimulates and potentiates corticoliberin-induced corticotropin secretion by activating a specific anterior pituitary receptor, recently cloned from mouse, rat, and human, and designated as V1b, or V4 receptor (De Keyzer et al., 1994; Sugimoto et al., 1994; Ventura et al., 1999). Indeed, molecular cloning of this receptor has provided key information concerning the cDNA expression in rat and human tissues, the localization of the V1b protein in the rat CNS and binding/signal transduction characterization due to stable expression of this cloned receptor in mammalian cells (Lolait et al., 1995b; Thibonni et al., 1997; Vaccari et al., 1998). However, the precise functional role of the V1b receptor is still obscure due to the lack of selective V1b receptor ligands and orally active molecules, which are crucial tools for investigating the central and peripheral functions or pathological disorders associated with this receptor.

The present study reports the biochemical and pharmacological characterization of SSR149415, the first selective, nonpeptide V1b receptor antagonist described so far, with potent oral antagonist effects on corticotropin secretion and anxiolytic-like properties in rodents. This new compound (Fig. 1), belonging to an original chemical series, shows high affinity and marked selectivity for AVP V1b receptors from animal and human origin, expressed in CHO cells or from native pituitary tissues (Table 1). Because species differences are very common in the field of AVP/OT receptors (Pettibone et al., 1992; Serradeil-Le Gal et al., 1993), it is important to emphasize that SSR149415 exhibits a similar nanomolar affinity for V1b receptors in the different species studied. In binding studies with [3H]AVP as a ligand, SSR149415 behaves as a fully competitive antagonist at human V1b receptors (Fig. 2B) and displayed a K<sub>i</sub> value close to that obtained for the natural hormone, AVP, and about 10-fold higher than the (V1a, V1b) peptide antagonist dPen, used as a reference tool up to now.

The highly selective V1b profile of SSR149415 is an important characteristic of this molecule. First, in vitro, this compound has low affinity for the three other AVP/OT-related receptors both from rat and human origin (Table 1). Second, at the highest doses used to block the V1b receptors in vivo (10 mg/kg i.p. and 30 mg/kg p.o.), SSR149415 does not modify the V1a vascular response to AVP in conscious rats nor the urine flow rate controlled by renal V2 receptors, both in normally hydrated and vasopressin-deficient Brattleboro rats. Third, the total lack of interaction of 10 μM SSR149415 with SSR149415 was administered orally and plasma ACTH measured 1 h after the SSR149415 treatment. Values are the means ± S.E.M. Statistical analysis was performed using a one-way ANOVA followed by a Dunnett's test and the level of significance was taken as P < 0.05 for comparison with the SR121463-treated control group (*, P < 0.05; **, P < 0.01). ACTH, corticotropin.

**TABLE 2**
Effect of SSR149415 on restraint-stress-induced corticotropin secretion in conscious rats

| Test               | Dose | Corticotropin
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0 mg/kg i.p.</td>
<td>61.9 ± 8.0</td>
</tr>
<tr>
<td>Stress control</td>
<td>0 mg/kg i.p.</td>
<td>329.4 ± 33.1*</td>
</tr>
<tr>
<td>SSR149415 + stress</td>
<td>10 mg/kg i.p.</td>
<td>192.1 ± 28.7**</td>
</tr>
</tbody>
</table>

*p < 0.01 versus control.

**p < 0.01 versus stress control.

Fig. 6. Effect of SSR149415 on SR121463-induced plasma ACTH increase in conscious rats. Animals received first a high dose (10 mg/kg p.o.) of the aquaeric V2 receptor antagonist SR121463. One hour later, 1 to 30 mg/kg SSR149415 was administered orally and plasma ACTH measured 1 h after the SSR149415 treatment. Values are the means ± S.E.M. Statistical analysis was performed using a one-way ANOVA followed by a Dunnett's test and the level of significance was taken as P < 0.05 for comparison with the SR121463-treated control group (*, P < 0.05; **, P < 0.01). ACTH, corticotropin.

Fig. 7. Effects of acute and 7-day repeated treatments with SSR149415 in the four-plate test in mice, and time course of the acute effects. Data represent mean ± S.E.M. * P < 0.05; ** P < 0.01 (Dunnett’s or Student’s t test, or Kruskal-Wallis test). n = 10 to 15 animals.
with a large number of receptors, ion channels, or enzymes has been evidenced. Thus, this molecule constitutes a unique ligand for targeting specifically V₁b receptors. One could also expect a particularly safe profile judging from this highly selective pattern of action. Indeed, in vivo pharmacological studies performed using SSR149415 with acute and repeated treatments in mice and rats and described herein have confirmed the good tolerability of this drug.

The V₁b receptor antagonistic properties of SSR149415 have been demonstrated in vitro and in vivo. By hypophyseal V₁b receptor activation, AVP directly stimulates corticotropin secretion and powerfully synergizes with corticotropin releasing hormone (Thibonnier et al., 1997, 1998). In our hands, SSR149415 behaves as a potent antagonist of AVP-induced [Ca²⁺], increase in CHO cells expressing either rat or human V₁b receptors. The Kᵥ value obtained around 1 nM is consistent with the nanomolar affinity found in binding studies by using the same cellular preparations. Of note, SSR149415 was devoid of any agonist effect per se. In vivo, pharmacology performed measuring corticotropin secretion induced by various stimulants such as hormones and physical stress confirmed the full antagonist profile of SSR149415. In all these situations, SSR149415 antagonized corticotropin secretion, which constitutes a critical response of the organism to stress in emotional situations. The direct corticotropin response to exogenous stimuli, such as AVP, AVP plus corticotropin-releasing hormone, and to endogenous AVP increase subsequent to important body water loss or physical stress, was dose dependently inhibited by SSR149415 from the oral doses of 3 or 10 mg/kg, according to the model. It is important to note that SSR149415 demonstrated higher efficacy on the potentiation of corticosterone effect by AVP, a mechanism described as a typical V₁b-mediated effect. In this latter model, significant inhibition of corticotropin secretion was observed from the oral dose of 3 mg/kg, total blockade occurred at 10 mg/kg p.o., and this effect lasted for more than 4 h. It is worth noting that corticotropin levels are highly increased (at least 6-fold versus basal values) after body water loss/dehydration induced by V₂ receptor antagonist, which could explain a somewhat lower efficacy of SSR149415 in this extreme situation. The lower corticotropin increase observed after the injection of exogenous 0.3 µg/kg i.v. AVP than after the elevation of endogenous AVP induced by SR121463 could be explained by the fact that the strong dehydration induced by the high dose of the aquaretic compound (10 mg/kg p.o.) provokes central AVP secretion, which rapidly activates nearby anterior pituitary V₁b receptors. Conversely, intravenous exogenous AVP could be subject to plasmatic degradation during its blood transport and lower concentrations of AVP could be available at pituitary V₁b receptors.

SSR149415 also antagonized the effects of restraint stress in rats as measured by the significant decrease in corticotropin secretion induced by the immobilization period (50% at 10 mg/kg i.p.). Thus, the regulation of corticotropin plasma levels, and consequently of the HPA axis in these situations, are largely mediated by V₁b receptors and SSR149415 offers a new tool to control emotional or physical stress. Indeed, several neuroendocrine studies strongly suggest that dysregulation of the HPA system plays a causal role in the development and the course of diseases such as generalized anxiety, depression, and addiction. In addition, many clinical conditions are accompanied by an exaggerated response to stress (Holsboer, 1999). One can speculate that all such situations are potential indications for the use of V₁b receptor antagonists since these disorders have been associated with excessive HPA activity in both humans and animals. We demonstrated that SSR149415 displayed anxiolytic-like activity in the four-plate test in mice a well validated model of anxiety sensitive to the action of various classes of anxiolytics such as benzodiazepines, metabolotropic glutamate receptor ligands, and 5-hydroxytryptamine uptake inhibitors (Bourin et al., 1992; Klotzinska et al., 1999; Hascoet et al., 2000; Tatarczynska et al., 2001). In this test, SSR149415 induces a marked, dose-dependent increase in punished responding, an effect that is indicative of an anxiolytic-like activity. Moreover, these effects are not accompanied by undesirable side effects such as sedation, decrease in spontaneous locomotor activity, or motor coordination disturbance (data not shown). Two additional experiments performed in the four-plate test showed that the anxiolytic-like activity of 10 mg/kg SSR149415 lasted for more than 4 h and was still present after repeated administration of the drug for 7 days, indicating first, a long-lasting oral effect for SSR149415, and second, no development of tolerance to the anxiolytic-like activity of the drug. Interestingly, a recent report has described the first mice carrying a null mutation of the V₁b receptors (Lolait et al., 2000; Hernando et al., 2001). In keeping with the anxiolytic-like properties of SSR149415, knockout mice displayed behavioral alterations such as reduced aggression, confirming the role of V₁b receptors in anxiety. Moreover, the V₁b receptor protein has a surprisingly wide distribution in the rat brain as recently shown by immunohistochemistry. In particular V₁b receptor immunoreactivity was observed in the hypothalamus, amygdala, cerebellum, and in areas close to circumventricular organs devoid of a blood-brain barrier (Hernando et al., 2001). This localization in key brain structures associated with specific central functions also strongly supports a role of central V₁b receptors in learning, memory, and various emotional and behavioral situations. Extensive studies are ongoing in our laboratory to further characterize the CNS pharmacological profile of SSR149415 in various animal models.

In conclusion, SSR149415 is a potent, selective, and orally effective V₁b receptor antagonist. It is a unique tool for exploring the role of V₁b receptors and deserves to be further investigated in various CNS disorders. This class of drug exhibits a promising therapeutic profile in the field of stress, anxiety, and depression.

Acknowledgments

We acknowledge Georgette Gout, Danielle Raufaste, Corinne Garcia, Éléonore Double-Cazanave, and Brigitte Pouzet for expert technical assistance. We thank the chemical team involved in the V₁b program and the Chemical Development Department for the synthe-
sis of SSR149415. We thank A. J. Patacchini-Young for comments on the manuscript and M. Laborde for excellent secretarial assistance.

References


Antoni FA, Holmes MC, Makara GB, Kertesz M, and Laszlo FA (1994) Evidence that the effect (V2) of antidiuretic hormone (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 5:519–522.


Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (IS0) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108.


Address correspondence to: Dr. Claudine Serradeil-Le Gal, Sanofi-Synthelabo Recherche, Exploratory Research Department, 195 route d’Espagne, 31068 Toulouse Cedex, France. E-mail: claudine.serradeil@sanofi-synthelabo.com